Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|S1400ANCILLARY||SWOG||Ancillary Study to Evaluate Patient and Physician Attitudes; Knowledge; and Expectations Related to Return of Genomic Results in Cancer in the SWOG 1400 (S1400) Clinical Trial||Adult CIRB - Late Phase Emphasis|
|S1702||SWOG||A Phase II Study of Isatuximab (SAR650984) for Patients with Previously Treated AL Amyloidosis||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-CC004||NRG||Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire In Women With Breast or Gynecologic Cancer||Cancer Prevention and Control CIRB||Available to Open|
|ALTE1631||COG||A Randomized Web-based Physical Activity Intervention among Children and Adolescents with Acute Lymphoblastic Leukemia||Pediatric CIRB||Available to Open|
|ACOSOG-Z1031||ACSOG||A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg daily); Letrozole (2.5 mg); or Anastrozole (1 mg) in Postmenopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|10031||ETCTN||A Phase 1 Study of PARP inhibitor olaparib and HSP90 inhibitor AT13387 for treatment of advanced solid tumors with expansion in patients with recurrent epithelial ovarian; fallopian tube; peritoneal cancer or recurrent triple-negative breast cancer||Adult CIRB - Early Phase Emphasis||Available to Open|
|AHEP0731||COG||Treatment of Children with All Stages of Hepatoblastoma with Temsirolimus (IND#122782; NSC#683864) Added to High Risk Stratum Treatment: A Groupwide Phase III Study||Pediatric CIRB||Available to Open|
|ALTE03N1||COG||Key Adverse Events after Childhood Cancer||Pediatric CIRB||Available to Open|
|S1500||SWOG||A Randomized; Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968]; Crizotinib [NSC #749005]; Savolitinib [NSC #785348]; and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)||Adult CIRB - Late Phase Emphasis||Available to Open|
|9672||ETCTN||A Phase 2 Study of Nivolumab in Advanced Leiomyosarcoma of the Uterus||Adult CIRB - Early Phase Emphasis||Available to Open|